Roche’s ovarian cancer treatment Avastin gets European approval
The approval in the European Union (EU) was based on results of the Phase III Aurelia trial which included women with recurrent, platinum-resistant ovarian cancer who received either
Mediar Therapeutics has announced a collaboration and option agreement with Ono Pharmaceutical to develop new treatments for fibro-inflammatory diseases.
Kadimastem will utilize its unique platform for Merck Serono, the biopharmaceutical division of Merck, for the screening of new compounds as potential new therapeutics. Kadimastem has developed a